AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Red hot chili peppers are 88% water, 9% carbohydrates, 2% protein, and 0.4% fat (table). In a 100 gram reference amount, chili peppers supply 40 calories, and are a rich source of vitamin C and vitamin B6.
== Diagnosis == The evaluation of a suspected myopathy combines clinical assessment with laboratory, electrophysiological, imaging, histological and genetic testing, since no single test is diagnostic for all forms.
An estimated 150 babies were born in Gaza per day since the start of the conflict. A pediatric doctor at the Emirati Hospital in Rafah, stated the number of premature babies born in Gaza had risen sharply. Newborn babies receiving specialized care in Israel and the West Bank while their mothers were trapped in Gaza. Oxfam stated newborn babies were dying from preventable diseases such as infection, hypothermia, diarrhea, and dehydration. By mid-December, parents were struggling to feed newborn babies, as mothers had insufficient nutrition to breastfeed. Newborn babies born during the conflict died in airstrikes, though some were rescued from the rubble. A UNOCHA representative stated she had met a woman forced to give birth in the street, and that the baby had died. One woman reported being unable to bathe her newborns more than ten days after their birth, due to the lack of clean water. Mothers reported extreme difficulty locating or affording milk and diapers for their newborns. In December 2023, an Israeli shell struck the largest fertility clinic in Gaza; the explosion knocked the lids off five liquid nitrogen tanks, causing temperature within the tanks to rise and destroying more than 4,000 embryos and 1,000 specimens of unfertilized eggs and sperm. According to Bahaeldeen Ghalayini, the obstetrician and gynaecologist who founded the clinic, the corner of the building was hit by a single shell, destroying the ground floor embryology lab; he does not know whether the strike was intentional or not.
Sources: en.wikipedia.org
==== Earth sciences ==== In Earth sciences, particularly in geomorphology, in situ refers to natural materials or processes occurring at their point of origin without being transported. An example is weathering, in which rocks undergo physical or chemical disintegration in place, in contrast to erosion, which involves the removal and relocation of materials by agents such as wind, water, or ice. Soil formed from the weathering of underlying bedrock is an example of an in situ formation. In situ measurements, such as those of soil moisture, rock stress, groundwater trends, or radiation levels, are conducted on-site to provide direct data. These measurements are often essential for validating remote sensing data, such as satellite imagery, which is widely used for large-scale environmental monitoring but may require in situ confirmation to ensure accuracy.
=== Immunoassays === Immunoassays require drawing blood and using the antibodies to find a reaction with substances such as drugs. The substances must be specific. It is the most common drug screening technique. Using the targeted drug the test will tell you if it is positive or negative to that drug. There can be 4 results when taking the test. Those results can be a true-positive, a false-negative, a false-positive, and a true-negative.
Thursday of the Dead is a feast day shared by Christians and Druze in the Lebanon, it falls sometime between the Easter Sundays of the Catholic and Eastern Orthodox Christian traditions. It is a day on which the souls of the dead are honoured. Particularly popular among women in the region, this occasion highlights the shared cultural heritage between Arab Christians and Druze in Lebanon. Additionally, the baptism of children in accordance with Christian customs often took place within prominent Lebanese Druze families. Common surnames among Lebanese Christians and Druze include Abi-Lamma, Assaf, Atrash, Awar, Ballout, Barakat, Daou, Dergham, Faour, Farraj, Ghannam, Halabi, Harb, Hatoum, Hilal, Ibrahim, Jaber, Kadamani, Kadi, Malaeb, Nammour, Safadi, Saker, Saleh, Serhal, Shaya, Timani, Yaghi, and others.
=== Electronic Submissions Gateway (ESG) === To standardize, automate and streamline the flow of regulatory data, FDA introduced an Electronic Submissions Gateway (ESG) in 2006. This gateway allows reporting organizations to send regulatory submissions to different centers over the internet, packaged in a center-specific format and enveloped as a GNU-compatible .tar.gz file, through either a FDA-specific WebTrader application or via a more generic B2B communication protocol called AS2 (Applicability Statement 2).
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.